Neos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Neos Therapeutics (NEOS) Tops Q4 EPS by 5c, Revenues Beat
March 14, 2019 7:09 AM EDTNeos Therapeutics (NASDAQ: NEOS) reported Q4 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $15.39 million versus the consensus estimate of $14.64 million.
In late November 2018, we unveiled a new commercial strategy for the company that includes an optimized salesforce... More
